

**Not for distribution, directly or indirectly,
in the United States of America, Australia, Canada or Japan**

MolMed: completed the third tranche of the share capital increase reserved to Société Générale pursuant to the “SEF - Standby Equity Facility” agreement

Milan, 22 September 2017 – Following the press release disclosed to the market on 21 September 2017, MolMed S.p.A. (MLM.MI) (“**MolMed**” or the “**Company**”) announces the settlement of the third tranche (the “**Third Tranche**”) of the share capital increase against payment, in one or more tranches, in divisible form, by and no later than 31 October 2018, without pre-emptive right pursuant to Article 2441, fourth paragraph, second sentence, of the Italian Civil Code, reserved to Société Générale (“**SG**”) in the context of the agreement named “SEF – Standby Equity Facility” executed on 6 October 2016 between Company and SG (the “**SEF Agreement**”).

Pursuant to the SEF Agreement and in respect of the Third Tranche, SG has undertaken to subscribe No. 9,011,721 MolMed ordinary shares, equal to 2.025% of the Company’s share capital, at a price equal to Euro 0.4173 per share (of which Euro 0.0471 represents capital and the remainder represents share premium), for a total amount of Euro 3,760,592.00.

Therefore, the Company has issued today No. 9,011,721 ordinary shares against payment of the relevant consideration by SG.

The new share capital of MolMed will be equal to Euro 20,949,084.36 divided into no. 444,962,393 ordinary shares with no par value.

Pursuant to the SEF Agreement, SG is not subject to any lock-up on the subscribed Shares, and the Company has not executed with SG any agreement for the resale of such shares on the market, nor any stock lending agreement or guarantee on the Shares is in place between the Company and SG.

It is reminded that the execution of the SEF Agreement will enable the Company to find resources, by benefiting from the flexibility of such tool, to satisfy the Company’s periodic liquidity needs, as well as to contribute to the development of the industrial plans, over the term of 24 months of the SEF Agreement.

The Shares issued in relation to the Third Tranche, together with any ordinary shares issued in the 12 months preceding the date of the utilization request, do not exceed 10% of MolMed ordinary shares already admitted to trading on the Italian Stock Exchange on the date of the relevant Utilization Request and, therefore, the Third Tranche of the Share Capital Increase is exempt from the obligation to publish a listing prospectus, pursuant to Article 57, paragraph 1, let. a) of the regulation approved by CONSOB resolution no. 11971/1999.

This press release is written in compliance with public disclosure obligations established by Consob’s (Italian securities & exchange commission) Issuers Regulation.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325

info@molmed.com - www.molmed.com

Share capital €20,524,632.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to market, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

For further information:

Laura Villa

Investor Relations & Communication Director

MolMed S.p.A.

phone: +39 02 21277.205

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Andrea Quaglino

Administration, Finance & Control Director

MolMed S.p.A.

phone: +39 02 21277.302

fax: +39 02 21277.404

e-mail: afc@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secrp.it